Olympus to Acquire BioProtect for $270 Million

May 27, 2026

Olympus signed a definitive agreement to acquire BioProtect for $270 million to expand its urology and oncology technology portfolio for prostate cancer care. The deal is expected to close by the end of Q2 2026, subject to customary closing conditions, with portions of the purchase price held in escrow tied to uninterrupted operation.

Buyers
Olympus Corporation
Targets
BioProtect Ltd.
Industry
Medical Devices
Location
Israel
Transaction Type
Buyout

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.